The Impact of Etanercept, Cyclosporine A, Triamcinolone Acetonide on Interleukin-23 in Experimental Autoimmune Uveitis
Tamer Demir1, Jülide
Kurt Keleş2, Fulya İlhan3 and Burak Turgut1*
1Department of Ophthalmology, Faculty of Medicine, Fırat
University, Elazig, Turkey
2Ophthalmology Clinic, Malatya State Hospital, Malatya, Turkey
*Corresponding author: Burak Turgut, Department of Ophthalmology, Faculty of Medicine, Fırat University, 23119, Elazig, Turkey, Tel: +90 4242333555; Fax: +90 4242388096; Email: drburakturgut@gmail.com
Received date: 29 March, 2016; Accepted date: 14 April, 2016; Published date: 28 April, 2016
Background: We aimed to investigate the effect of etanercept, Cyclosporine A
(CsA) and Triamcinolone Acetonide (TA) on Interleukin-23 (IL-23) in the
Experimental Autoimmune Uveitis (EAU) model.
Materials and methods: Thirty-five guinea pigs were divided into five
groups consisting seven animals in each: Group 1 (control group), Group 2 (sham
group), Group 3 (etanercept group) and Group 4 (CsA group) and Group 5 (TA
group). The experiments in Group 1 were not given any treatment. The single
eyes of all experiments in the groups except Group 1 administered intravitreally
1mg/ml concanavalin A to induce the EAU. On the 14th day, after clinical
confirmation of uveitis, the eyes of the animals in Group 2, 3 and 5 received
single dose intravitreally of 0.1ml saline, 2 mg/0.1 ml etanercept and 4 mg/0.1
ml TA, respectively. The animals in Group 4 were given intravitreally 100
μg/0.1 ml CsA weekly. At the end of the 6th week following the drug
administrations, the eyes, including also controls, were excised. Vitreous
IL-23 levels were measured by ELISA and evaluated.
Results: The mean IL-23 level in Group 2 was found to be higher than that
of Group 1 (p<0.05). There was no statistically significant difference in
the IL-23 levels among the treatment groups (Group 3, 4 and 5) (p>0.05).
Conclusion: This study suggests that intravitreal etanercept, CsA and TA do
not affect the levels of IL-23 in EAU model.
Keywords: Cyclosporine A; Etanercept; Experimental autoimmune uveitis;
Triamcinolone acetonide; IL-23
Uveitis is the inflammatory disease of the uvea. Although it may
be caused by autoimmune diseases, infections, or trauma, approximately half of
the cases with uveitis are idiopathic. It often courses with attacks and
remissions and can be complicated with permanent ocular damage and visual loss.
Although the exact pathogenic mechanism of uveitis is not known, it is clearly
demonstrated that pro-inflammatory cytokines such as Interleukin (IL)-1, IL-6,
and Tumor Necrosis Factor-alpha (TNF-α) play the important role in uveitis
[1,2]. Thus, the various anti-TNF agents in the treatment of uveitis have been
currently researched.
Etanercept that inhibits the action of both TNFα and TNFβ is a
fusion protein consisting the extracellular ligand-binding portion of human TNF
receptor p75 and the Fc portion of human IgG1. It has been used in the
treatment of autoimmune diseases such as Rheumatoid Arthritis (RA) and
ankylosing spondylitis [3-5]. It has been demonstrated that systemically or
intravitreal etanercept is efficacious in the treatment in both the patients
with chronic uveitis and Experimental Autoimmune Uveitis (EAU) [6-9].
Interleukin-23 is a member of the IL-12-related cytokine family.
It was firstly described by Kastelein et al., [10]. IL-23 plays the role in the
activation and proliferation and stabilization of Th17 which differentiated
before. IL-23 increases the lymphocyte proliferation, promotes the production
of IFN-γ [11-18]. In the Behcet’s patients with active uveitis, IL-23, IL-17
and IFN-γ levels were found to be significantly higher [19]. IL-23 is
responsible for the survival and amplification of Th17 cells as well as the
production of IL-22 and IL-21 [20]. It was observed that the receptor gene
expression of IL-23 has also been shown to increase in Inflammatory Bowel
Diseases (IBD), RA, psoriasis and Graves’ ophthalmopathy [21-23]. Additionally,
Chen et al., [14] showed that administration of anti-IL-23p19 mAb in
Experimental Autoimmune Encephalomyelitis (EAE), decreased central nervous
system expression and the serum level of IL-17. Thus, it is considered that
Th17 development is dependent on the presence of both IL-23 and IL-6. IL-23 may
function at a late stage of the differentiation of Th17 cell following initial
induction by other pro-inflammatory cytokines [16-18]. It was demonstrated that
the rats deficient in IL-23 were completely resistant to EAE [24,25]. Toussirot
et al., demonstrated that the IL-23/Th17 axis plays a key role in the
development of chronic inflammatory and autoimmune-mediated diseases [17]. It
was reported by Luger et al., [26] that systemic neutralization of IL-23
prevented the development of EAU.
We considered that etanercept will be able to affect the
vitreous IL-23 levels and conducted this study. In this study, we aimed to
investigate the effect of etanercept on IL-23, and to compare its effect with
those of CsA and TA in EAU.
Materials and Methods
This study was carried out in the single eye of each experiment,
with approval from the institutional ethics committee of Fırat University. All
procedures were performed with strict adherence to the guidelines for animal
care and experimentation prepared by the Association for Research in Vision and
Ophthalmology and Guidelines for the Housing of Rats in Scientific
Institutions.
The study included 35 male albino guinea pigs, of mean weight
400 g. The experiments were housed in special wire-bottomed cages at room
temperature on a 12-hour light-dark cycle in the experimental research center
at Fırat University along the study. They were fed with standard guinea pig
chow but were given only water 12 hours before surgery.
The experiments were randomly allocated to five groups, with
seven rats in each group: Group 1 (control group) was composed of the animals
which were not operated on and did not receive any treatment. Group 2 (sham
group) was composed of the animals in which induction of EAU was performed and
which received single dose intravitreally 0.1ml saline. Group 3 (etanercept
group) was composed of the animals in which induction of EAU was performed and
which received intravitreally single dose 2 mg/0.1 ml etanercept (Enbrel, Wyeth
Pharmaceuticals, Philadelphia, PA, USA). Group 4 (cyclosporine A-CsA-group) was
composed of the animals in which induction of EAU was performed and which
received intravitreally 100 μg/0.1 ml cyclosporin A (Sandimmune 50 mg/ml
ampoule, Novartis Pharma AG, Basel, Switzerland) weekly. Group 5 (triamcinolone
acetonide-TA-group) was composed of the animals in which induction of EAU was
performed and which received intravitreally single dose 4 mg/0.1 ml
triamcinolone acetonide (Kenacort A 40 mg/ml ampoule, Bristol-Myers Squibb Co.,
Princeton, NJ, USA).
At the end of the 6th week following the drug administrations,
the enucleation of eyes was performed following induction of analgesia and
anesthesia.
Induction of EAU
The animals in the groups except the control group were injected
intravitreally with concanavalin A (Sigma Chemical Co, St Louis, MO) 1 mg/mL in
the right eye only. Drug administration was started when uveitis-like
inflammation developed 2 weeks later. Topical antibiotic drops were instilled
into eyes.
Anesthetic and surgical technique
A combination of ketamine hydrochloride 50 mg/kg (Ketalar®,
Eczacıbaşı, Turkey) and xylazine hydrochloride 5 mg/kg (Rompun®, Bayer,
Turkey) was intramuscularly injected to induce anesthesia and analgesia.
After induction of anesthesia and analgesia, 1 mg/0.1 mL
concanavalin A was injected using a 30-gauge needle into the right eye only,
except in the animals in the control group. At the end of the second week,
slit-lamp biomicroscopy revealed flare in the anterior chamber, moderate cell
numbers, fibrin behind the lens, and moderate cataract. After the development
of uveitis was confirmed clinically, the sham and treatment groups were given
intravitreal injections at the end of the second week. At the end of 6th week, the eyes
of the experiments were enucleated. Vitreous samples were obtained by
aspiration using a 27-gauge needle and sent to immunology laboratory for the
measurement of vitreous IL-23 levels.
Immunological evaluation of vitreous IL-23 levels
IL-23 levels in vitreous samples of the experiments were
measured by mouse IL-23 (p19/p40) kit (eBioscience, San Diego, CA) using the
solid phase sandwich Enzyme-Linked Immunosorbent Assay (ELISA). The detection
limit for this assay was 1.0 pg/ml. The assays were performed according to the
manufacturers’ instructions. Results are expressed in picogram per milliliter
as a mean ± standard deviation.
Histopathologically confirmation of EAU
The histopathological findings including heavy infiltration of
inflammatory cells, edema, congestion of the retina and uvea and proliferation
in the ciliary epithelium after intravitreal injection of concanavalin A were
interpreted as evidence of induction of uveitis.
Statistical analyses
The means (±standard deviations) of the data obtained were
calculated. The statistical analysis was carried out using the Statistical
Package for Social Sciences version 13 (SPSS Inc, Chicago, IL). Analysis of
variance was carried out for multiple comparisons using the Kruskal-Wallis test
and the Mann-Whitney U test was used for dual comparisons between groups. A P
value less 0.05 was accepted as being statistically significant.
Results
The mean vitreous IL-23 levels were found as 2.75±0.22, 3.49±0.34,
3.83±0.10, 3.53±0.17 and 3.73±0.25 pg/ml, respectively. The mean vitreous IL-23
levels in the sham and treatment groups were significantly higher than control
(p<0.01). There was no significant difference among sham and treatment
groups in terms with IL-23 levels (p>0.05). When compared with control
group, IL-23 levels were observed to be higher in each treatment group
(p<0.001) (Table 1 and figure 1).
Additionally, the comparison of edema, tissue congestion,
Mononuclear Cell (MNC) and Polymorphonuclear Leukocyte (PNL) infiltration in
the study groups was given in table 1.
Discussion
Uveitis, the inflammatory disease of the uvea is responsible for
10% of legal blindness [1]. Although, there is currently no effective treatment
for the uveitis, glucocorticosteroids and some immunosuppressive agents have
been widely used in the treatment of disease [2]. Although many cytokines
contributed to uveitis, the minority of them play significant roles. TNF-α
stimulates mononuclear phagocytes as well as other cell types that produce
IL-1, IL-6 and chemokines, and induces the migration of PNL [1,27-29]. Recent
studies have shown that a new T helper subset that produces IL-17 (Th17) is
also involved in the development of EAU [25-30]. The animal models have been
demonstrated that the number of T-helper types 17 cell (Th17) increased in the
active uveitis and scleritis while it reduced after treatment [31-33].
IL-23, a member of the IL-12 family of cytokines, is a
heterodimeric cytokine composed of the p40, shared with IL-12, and p19, a
subunit that belongs to the IL-6 superfamily of cytokines [10-13]. IL-23 is
synthesized by activated macrophages and the dendritic cells with the
stimulation of immune triggers such as bacterial products, viral infection and
pro-inflammatory cytokines or CD40 signaling and regulate TH17 function and
proliferation [16-21]. Additionally, IL-23 induces CD8+ memory T cells to
proliferate and produce IL-17 [12,34-39].
IL-23 binds to a heterodimeric receptor composed of IL-12Rβ1 and
IL-23R. Th17 cells are enriched for expression of IL23R [16-21]. IL-23 plays an
important role in chronic inflammatory responses and the pathogenesis of some
autoimmune inflammatory disorders [12,16,34-39]. It has been demonstrated in
recent studies that IL-23-deficient (IL-23p19−/−) mice are resistant to EAE,
IBD and EAU [21,22]. IL-23 also affects the innate immune system, inducing the
production of pro-inflammatory cytokines [10,21]. Recent studies demonstrated
that blood levels of IL-23, IL-17 and IFN-γ simultaneously increased in
intraocular inflammation in Behcet’s disease [19,34].
In the mice formed IL-23 gene disorder, it has been observed
that the formation of EAE, arthritis, and IBD was not composed [24]. IL-23
increases the synthesis of IL-17 IL-17F, IL-6 and TNF-α from activated T cells
[10,25]. It has been considered that IL-23 that increases the levels of
cytokines such as TNF-α, IL-6, IL-17 and IFN-γ is the orchestrating conductor
of the inflammatory cascade [35,36].
In the patients with IBD, it was demonstrated that IL-23
stimulated the expression of Th17 cells and the synthesis of IL-17 [40]. It has
been suggested that IL-23 might play in role in the development of uveitis in
Vogt-Koyanagi-Harada disease via the stimulation of IL-17-producing CD4+ T
cells [11]. Caspi et al., reported that IL-23 and a Th17 effector response
affected by IL-23 are needed for the development of uveitis [41]. In recent
studies, it has been observed that mice given IL-12/IL-23 inhibitor did not
develop IL-23 response and the increase of IL-17 [42]. In our study, it was
found that IL-23 level elevated in uveitis created eyes (sham group).
Etanercept is a soluble fusion protein produced by recombinant
DNA of the extracellular ligand-binding portion of human TNF receptor p75 and
the Fc portion of human IgG1. This agent inhibits the action of both TNF-α and
TNF-β, important pro-inflammatory cytokines [5-11]. Etanercept is a large
molecule with a molecular weight of 150 kDa. It binds to TNF-α and decreases
its effect in disorders involving excess inflammation in humans and animals,
including autoimmune diseases such as ankylosing spondylitis, juvenile RA,
psoriasis, psoriatic arthritis, RA, and potentially, in various disorders
mediated by excess TNF-α such as uveitis [5-9,43-45].
In rats formed EAU, TNF-α antagonists decreased the severity of
uveitis [47]. Etanercept treatment in the patients with RA decreased serum
IL-23 levels [43,44]. In another study, it was observed that the etanercept
treatment suppressed the proliferation of Th17 in psoriasis patients and
suggested that it was probably related to the decrease in the level of IL-23
[45]. In our study, we observed that etanercept did not affect vitreous IL-23
levels in EAU model. These results contradict with the thought that anti-TNF
therapy to suppress IL-23 synthesis. This may be caused by a diversity in
cytokine cascade due to a change in Th polarization in various diseases such as
RA and psoriasis.
Cyclosporine A is a T cell-specific immunosuppressant, which
affects the early phase of the immune response via the blockade of the
synthesis and release of IL-1 from by macrophages and IL-2 from by Th cells.
CsA has been shown to be effective in the treatment of immune-mediated ocular
diseases such as uveitis [47-50]. IL-23 is synthesized by macrophages and
dendritic cells. CsA affects the functions of dendritic cells [51]. However, in
our study, we also found that CsA did not affect IL-23 levels in EAU.
IL-23 leads to synthesis the inflammatory cytokines through
IL-12Rβ1 receptors. Glucocorticoids inhibit Th cells and antigen-presenting
cells and the expression of various cytokines released by T1 and T2 lymphocytes
and eventually suppresses the inflammation. Thus, they have been widely used
uveitis [52-54]. Dexamethasone treatment has been shown to decrease the
expression of IL-12Rβ1 [55]. In in vitro studies, it has been
observed that the cytokine synthesis induced by IL-23 was suppressed when
dexamethasone was added to medium [55]. In our study, we found that TA did not
statistically significantly affect IL-23 levels. This is compatible with that
fact of the TA acts decreasing the expression of IL-12Rβ1 but not inhibiting
the IL-23 synthesis. Reduction of receptor expression with TA has been provided
the blockade of the inflammatory effects of IL-23, however, this has not
affected the IL-23 levels.
Despite it was provided significant clinical improvement after
etanercept, CsA and TA treatments in EAU, drugs failed to provide a reduction
in IL-23 level. In conclusion, we consider that IL-23 does not affect only Th17
proliferation and it may affect other pathways in the inflammatory cascade in
uveitis.
As a result, etanercept, CsA and TA failed to suppress vitreal
IL-23 in EAU model. Further studies are needed to understand the exact effects
of etanercept in the suppression of the inflammation.
Figure 1: The graphic presents the comparison of the mean vitreous IL-23 levels in the study groups.
|
Control |
Sham |
Etanercept |
Cyclosporine A |
Triamcinolone |
---|---|---|---|---|---|
IL-23 (pg/ml) |
2.75± 0.22* | 3.49±0.34 | 3.83±0.10 | 3.53±0.17 | 3.73±0.25 |
Congestion |
0.43± 0.53* | 1.86±0.69 | 1.57±0.53 | 1.71±0.75 | 1.43±0.78 |
MNC Infiltration |
0.43± 0.53* | 2.43±0.78 | 1.00±0.00* | 1.14±0.38* | 1.43±0.53* |
PNL Infiltration |
0.71±0.48* | 1.14± 0.37 | 0.86±0.37 | 2.29±0.95* | 1.00± 0.00 |
Edema |
0.86± 0.37* | 1.86±0.37 | 2.00±0.57 | 1.00±0.00* | 1.29±0.48* |
Table 1: The mean levels of IL-23, mean values of congestion, MNC and PNL infiltration and edema in the study groups.
IL: Interleukin; MNC: Mononuclear Cell; PNL:
Polymorphonuclear Leukocyte Compared to the sham group: *p<0.05
- Ooi KG, Galatowicz G, Calder VL,
Lightman SL (2006) Cytokines and chemokines in uveitis: is there a correlation
with clinical phenotype? Clin Med Res 4: 294-309.
- Bierly JR, Nozik RA
(1992) Management of uveitis. Current Opinion in Ophthalmology 3: 527-533.
- Imrie FR, Dick AD (2007) Biologics in the
treatment of uveitis. Curr Opin Ophthalmol 18: 481-486.
- Lim L, Suhler EB,
Smith JR (2006) Biologic therapies for inflammatory eye disease. Clinical &
Experimental Ophthalmology 34: 365-374.
- Takeuchi M (2013) A systematic review of
biologics for the treatment of noninfectious uveitis. Immunotherapy 5: 91-102.
- Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert
B, et al. (1996) Anti-tumor necrosis factor alpha therapy suppresses the
induction of experimental autoimmune uveoretinitis in mice by inhibiting
antigen priming. Invest Ophthalmol Vis Sci 37: 2211-2218.
- Tynjälä P, Lindahl P, Honkanen V, Lahdenne P,
Kotaniemi K (2007) Infliximab and etanercept in the treatment of chronic
uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis
66: 548-550.
- Taban M, Dupps WJ, Mandell B, Perez VL (2006)
Etanercept (Enbrel)-associated inflammatory eye disease: case report and review
of the literature. Ocul Immunol Inflamm 14: 145-150.
- Busch M, Bauer D, Hennig M, Wasmuth S, Thanos S,
et al. (2013) Effects of systemic and intravitreal TNF-α inhibition in
experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 54: 39-46.
- Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, et
al. (2001) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with
biological activities similar as well as distinct from IL-12. Immunity 13:
715-725.
- Chi W, Yang P, Li B, Wu C, Jin H, et al. (2007)
IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J
Allergy Clin Immuno 119: 1218-1224.
- Liang D, Zuo A, Shao H, Born WK, O’Brien RL, et
al. (2013) IL-23 receptor expression on γδ T cells correlates with their
enhancing or suppressive effects on autoreactive T cells in experimental
autoimmune uveitis. J Immunol 191: 1118-1125.
- Iwakura Y, Ishigame H (2006) The IL-23/IL-17
axis in inflammation. J Clin Invest 116: 1218-1222.
- Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B,
Stumhofer JS, et al. (2006) Anti-IL-23 therapy inhibits multiple inflammatory
pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116:
1317-1326.
- Caspi RR, Roberge FG, Chan CC, Wiggert B, Chader
GJ, et al. (1988) A new model of autoimmune disease. Experimental autoimmune
uveoretinitis induced in mice with two different retinal antigens. J Immunol
140: 1490-1495.
- Sieve AN, Meeks KD, Lee S, Berg RE (2010) A
novel immunoregulatory function for IL-23: Inhibition of IL-12-dependent IFN-γ
Eur J Immunol 40: 2236-2247.
- Toussirot E (2012) The IL23/Th17 pathway as a
therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug
Targets 11: 159-168.
- Parham C, Chirica M, Timans J, Vaisberg E,
Travis M, et al. (2000) A receptor for the heterodimeric cytokine IL-23 is
composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J
Immunol 168: 5699-5708.
- Chi
W, Zhu X, Yang P, Liu X, Lin X, et al. (2008) Upregulated IL-23 and IL-17 in
Behçet Patients with Active Uveitis. Invest Ophthalmol Vis Sci 49: 3058-3064.
- Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S,
et al. (2012) Induction and molecular signature of pathogenic TH17 cells. Nat
Immunol 13: 991-999.
- Teng MW, Bowman EP, McElwee JJ, Smyth MJ,
Casanova JL, et al. (2015) IL-12 and IL-23 cytokines: from discovery to
targeted therapies for immune-mediated inflammatory diseases. Nat Med 21:
719-729.
- Cătană CS, Berindan Neagoe I, Cozma V, Magdaş
C, Tăbăran F, et al. (2015) Contribution of the IL-17/IL-23 axis to the
pathogenesis of inflammatory bowel disease. World J Gastroenterol 21: 5823-5830.
- Yen D, Cheung J, Scheerens H, Poulet F,
McClanahan T, et al. (2006) IL-23 is essential for T cell-mediated colitis and
promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310-1316.
- Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B,
et al. (2003) Interleukin-23 rather than interleukin-12 is the critical
cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
- Murphy CA, Langrish CL, Chen Y, Blumenschein W,
McClanahan T, et al. (2003) Divergent pro- and anti-inflammatory roles for
IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198: 1951-1957.
- Luger D, Silver PB, Tang J, Cua D, Chen Z, et
al. (2008) Either a Th17 or a Th1 effector response can drive autoimmunity:
conditions of disease induction affect dominant effector category. J Exp Med
205: 799-810.
- Sun M, Yang Y, Yang
P, Lei B, Du L, et al. (2011) Regulatory effects of IFN-β on the development of
experimental autoimmune uveoretinitis in B10RIII mice. PLoS One 6: 19870.
- Kawashima H, Fujino Y, Mochizuki M (1990)
Antigen-specific suppressor cells induced by FK506 in experimental autoimmune
uveoretinitis in the rat. Invest Ophthalmol Vis Sci 31: 2500-2507.
- Luger D, Caspi RR (2008) New perspectives on
effector mechanisms in uveitis. Semin Immunopathol 30: 135-143.
- Horai R, Caspi RR (2011) Cytokines in autoimmune
uveitis. J Interferon Cytokine Res 31: 733-744.
- Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL,
et al. (2007) TH17 cells contribute to uveitis and scleritis and are expanded
by IL-2 and inhibited by IL-27/STAT1. Nat Med 13: 711-718.
- Yoshimura T, Sonoda KH, Miyazaki Y, Iwakura Y,
Ishibashi T, et al. (2008) Differential roles for IFN-gamma and IL-17 in
experimental autoimmune uveoretinitis. Int Immunol 20: 209-214.
- Yoshimura T, Sonoda KH, Ohguro N, Ohsugi Y,
Ishibashi T, et al. (2009) Involvement of Th17 cells and the effect of
anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 48: 347-354.
- Kullberg MC, Jankovic D, Feng CG, Hue S,
Gorelick PL, et al. (2006) IL-23 plays a key role in Helicobacter
hepaticus-induced T cell-dependent colitis. J Exp Med 203: 2485-2494.
- Hue S, Ahern P, Buonocore S, Kullberg MC, Cua
DJ, et al. (2006) Interleukin-23 drives innate and T cell-mediated intestinal
inflammation. J Exp Med 203: 2473-2483.
- Niimi N, Kohyama K, Matsumoto Y (2013)
Therapeutic gene silencing with siRNA for IL-23 but not for IL-17 suppresses
the development of experimental autoimmune encephalomyelitis in rats. J
Neuroimmunol 254: 39-45.
- Leonard JP, Waldburger KE, Goldman SJ (1995) Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 181: 381-386.
- Becher B, Durell BG, Noelle RJ (2002)
Experimental autoimmune encephalitis and inflammation in the absence of
interleukin-12. J Clin Invest110: 493-497.
- Chan JR, Blumenschein W, Murphy E, Diveu C,
Wiekowski M, et al. (2006) IL-23 stimulates epidermal hyperplasia via TNF and
IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J
Exp Med 203: 2577-2587.
- Kobayashi T, Okamota S, Hisamatsa T, Kamada N,
Chinen H, et al. (2008) IL-23 differentially regulates the Th1/Th17 balance in
ulcerative colitis and Crohn’s disease. Gut 57: 1682-1689.
- Caspi R, Silver P,
Cua D, Chen Z, Chi-Chao Chan (2007) IL-23 and IL-17 in pathogenesis of
experimental ocular autoimmunity: requirement for IL-23 may extend beyond its
role in sustaining the IL-17 effector response. J Immunol 178: 129.
- Keino H, Watanabe T, Sato Y, Niikura M, Wada Y,
et al. (2008) Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326
on experimental autoimmune uveoretinitis. Arthritis Res Ther 10:1-8.
- Kageyama Y, Ichikawa T, Nagafusa T, Torikai E,
Shimazu M, et al. (2007) Etanercept reduces the serum levels of interleukin-23
and macrophage inflammatory protein-3 alpha in patients with rheumatoid
arthritis. Rheumatol Int 28: 137-143.
- Zaba LC, Cardinale I, Gilleaudeau P,
Sullivan-Whalen M, Suárez-Fariñas M, et al. (2007) Amelioration of epidermal
hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp
Med 204: 3183-3194.
- Caproni M, Antiga E, Melan L, Volpi W, Del
Bianco E, et al. (2009) Serum Levels of IL-17 and IL-22 are Reduced by
Etanercept, but not by Acitretin, in Patients with Psoriasis: a
Randomized-Controlled Trial. J Clin Immunol 29: 210-214.
- Dick AD, McMenamin PG, Korner H, Scallon BJ,
Ghrayeb J, et al. (1996) Inhibition of tumor necrosis factor activity minimizes
target organ damage in experimental autoimmune uveoretinitis despite
quantitatively normal activated T cell traffic to the retina. Eur J Immunol 26:
1018-1025.
- Pazderka F, Enns J, Batiuk TD, Halloran PF
(1996) The functional consequences of partial calcineurin inhibition in human
peripheral blood mononuclear leucocytes. Transpl Immunol 4: 23-31.
- Masuda K, Nakajima A, Urayama A, Nakae K, Kogure
M, et al. (1989) Double-masked trial of cyclosporin versus colchicine and
long-term open study of cyclosporine in Behcet’s disease. Lancet 1: 1093-1096.
- Nussenblatt RB, Rodrigues MM, Salinas-Carmona
MC, Gery I, Cevario S, et al. (1982) Modulation of experimental autoimmune
uveitis with cyclosporin A. Arch Ophthalmol 100: 1146-1149.
- Nussenblatt RB, Palestine AG, Chan CC (1983)
Cyclosporin A therapy in the treatment of intraocular inflammatory disease
resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 96:
275-282.
- Toebak MJ, de Rooij J, Moed H, Stoof TJ, von
Blomberg BM, et al. (2008) Differential suppression of dendritic cell cytokine
production by anti-inflammatory drugs. Br J Dermatol 158: 225-233.
- Liu X, Yang P, Lin X, Ren X, Zhou H, et al.
(2009) Inhibitory effect of cyclosporin A and corticosteroids on the production
of IFN-γ and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol
131: 333-342.
- Yang
K, Wen J, Liu X, Kijlstra A, Chen L, et al. (2009) Inhibitory effect of
rapamycin and dexamethasone on production of IL-17 and IFN-γ in
Vogt-Koyanagi-Harada patients. Br J Ophthalmol 93: 249-253.
- Marchant A, Amraoui Z, Gueydan C, Bruyns C, Le
Moine O, et al. (1996) Methylprednisolone differentially regulates IL-10 and
Tumour Necrosis Factor (TNF) production during murine endotoxaemia. Clin Exp
Immunol 106: 91-96.
- Fahey AJ, Robins RA, Kindle KB, Heery DM,
Constantinescu CS (2006) Effects of glucocorticoids on STAT4 activation in
human T cells are stimulus-dependent. J Leukoc Biol 80: 133-144.
© by the Authors & Gavin Publishers. This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. Read More About Open Access Policy.